Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO )
Dr. Hazel returns to Neuralstem after a four year stint as Chief ScienceOfficer at Innovative BioSensors, in Maryland. Prior to that, Dr. Hazelworked with Dr. Johe at Neuralstem for four years to develop the company'stechniques for isolating and growing human neural stem cells. BeforeNeuralstem in 1998, Dr. Hazel worked as a Senior Staff Scientist at theNational Institute of Health, which he joined after receiving his Ph.D. inGenetics from the University of Illinois.
Advertisement
"Tom has the background to make a substantial contribution the day hearrives," observed Dr. Johe. "I expect this to accelerate our productdevelopment cycle."
"Tom's addition to our senior management team will increase its depth,expand the range of partners that we can work with worldwide, and speed up ourprogress to market," commented Neuralstem CEO, Richard Garr. "This is animportant hire for us."
About Neuralstem
Neuralstem's patented technology enables, for the first time, the abilityto produce neural stem cells of the human brain and spinal cord in commercialquantities, and the ability to control the differentiation of these cells intomature, physiologically relevant human neurons and glia. The Company iscurrently targeting diseases and injuries of the spinal cord for its firsthuman trials, including ALS and Paraplegia.
The company has also developed neurogenic and neuroprotective smallmolecule compounds targeted at treating depression. For further information,please visit http://www.neuralstem.com.
Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements made pursuant tothe "safe harbor" provisions of the Private Securities Litigation Reform Actof 1995. Investors are cautioned that such forward-looking statements in thispress release regarding potential applications of Neuralstem's technologiesconstitute forward-looking statements that involve risks and uncertainties,including, without limitation, risks inherent in the development andcommercialization of potential products, uncertainty of clinical trial resultsor regulatory approvals or clearances, need for future capital, dependenceupon collaborators and maintenance of our intellectual property rights. Actualresults may differ materially from the results anticipated in theseforward- looking statements. Additional information on potential factors thatcould affect our results and other risks and uncertainties are detailed fromtime to time in Neuralstem's periodic reports, including the annual report onForm 10-KSB for the year ended December 31, 2007 and the quarterly report onform 10-Q for the period ended March 31, 2008.
SOURCE Neuralstem, Inc.
